Bessemer Group’s Impax Laboratories, Inc. IPXL Stock Holding History

Bessemer Group’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-127	Closed	-$2K	–	2014
2016 Q4	$2K	Buy	+127	New	+$2.17K	﹤0.01%	1879

Other funds holding IPXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NTC

North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Bessemer Group's IPXL Position: Q1 2017 in Review

Bessemer Group sold out of Impax Laboratories, Inc. (IPXL) in Q1 2017, closing a stake of 127 shares — an estimated $2K sold.

Bessemer Group first reported a position in IPXL in Q4 2016 and held it in 1 quarter. The position peaked at $2K in Q4 2016. 178 funds tracked by Wall St. Rank hold IPXL as of Q1 2017.

Bessemer Group reported no remaining Impax Laboratories, Inc. position as of Q1 2017 after selling out during the quarter.
Bessemer Group sold 127 Impax Laboratories, Inc. shares in Q1 2017, an estimated $2K.
Bessemer Group first reported a position in Impax Laboratories, Inc. in Q4 2016 and held it in 1 quarter.
Bessemer Group's Impax Laboratories, Inc. position peaked at $2K in Q4 2016.
178 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q1 2017.

Based on Bessemer Group's 13F filing for Q1 2017, filed 12 May 2017.